Management of pain in the elderly at the end of life

Drugs and Aging

Volumn 29, Issue 4, 2012, Pages 285-305

  Prommer, Eric ^a   Ficek, Brandy ^a  

^a MAYO CLINIC   (United States)

Author keywords

Analgesics; Elderly; Non opioid analgesics; Opioid analgesics; Pain; Palliative care.

Indexed keywords

ANALGESIC AGENT; CODEINE; DICLOFENAC; DIHYDROCODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; INDOMETACIN; INTERLEUKIN 1; KETAMINE; KETOPROFEN; KETOROLAC; LEVORPHANOL; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NAPROXEN; OPIATE; OXAPROZIN; OXYCODONE; PARACETAMOL; PIROXICAM; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE C; SULINDAC; TRAMADOL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AGED; ANALGESIA; ANXIETY; BONE PAIN; BRIEF PAIN INVENTORY; CANCER PAIN; CANCER PATIENT; CELL MEMBRANE; CHRONIC PAIN; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONSTIPATION; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; ELDERLY CARE; FATIGUE; GERIATRIC PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPNOSIS; IMMUNOCOMPETENT CELL; INSOMNIA; KIDNEY DISEASE; MACROPHAGE; MCGILL PAIN QUESTIONNAIRE; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; PAIN; PAIN ASSESSMENT; PATIENT EDUCATION; PEPTIC ULCER; PERISTALSIS; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; PSYCHOTHERAPY; RASH; RELAXATION TRAINING; REVIEW; SIDE EFFECT; SWEATING; TISSUE INJURY; VISCERAL PAIN; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

AGED; ANALGESICS; DRUG ADMINISTRATION ROUTES; HUMANS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; TERMINAL CARE;

EID: 84859457360     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11599210-000000000-00000     Document Type: Review

References (146)

1. Thomas JR, Von Gunten CF. Pain in terminally ill patients: guidelines for pharmacological management. CNS Drugs 2003; 17 (9): 621-31 (Pubitemid 36920540)
2. Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging 2003; 20 (1): 23-57 (Pubitemid 36127032)
3. Nordgren L, Sörensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J Cardiovasc Nurs 2003; 2 (3): 213-7 (Pubitemid 37153169)
4. Grond S, Zech D, Schug SA, et al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991; 6 (7): 411-22
5. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004; 9 (5): 571-91 (Pubitemid 39332322)
6. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61 (2): 277-84
7. Cherny NI, Portenoy RK. Cancer pain: principles of assessment and syndromes. In: Wall PD, Melzack R, editors. Textbook of pain. 4th ed. London: Churchill Livingstone, 1999: 1017-64
8. Bruera E, Kim HN. Cancer pain. JAMA 2003; 290 (18): 2476-9 (Pubitemid 37430548)
9. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41 (3): 273-81 (Pubitemid 20187930)
10. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005; 9 (2): 195-206 (Pubitemid 40311842)
11. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebocontrolled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998; 90 (8): 611-6 (Pubitemid 28204805)
12. Strang P, Strang S, Hultborn R, et al. Existential pain: an entity, a provocation, or a challenge? J Pain Symptom Manage 2004; 27 (3): 241-50 (Pubitemid 38317061)
13. Overcash J. Symptom management in the geriatric patient. Cancer Control 1998; 5 (3 Suppl. 1): 46-7 (Pubitemid 28298309)
14. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003; 106 (3): 337-45 (Pubitemid 37505881)
15. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004; 66 (1): 17-22 (Pubitemid 38146528)
16. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Pain 2000; 88: 2164-71 (Pubitemid 30233220)
17. Management of cancer pain: adults. Cancer Pain Guideline Panel. Agency for Health Care Policy and Research. Am Fam Physician 1994; 49 (8): 1853-68
18. Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 1987; 60 (5): 1151-8 (Pubitemid 17157235)
19. Graham C, Bond SS, Gerkovich MM, et al. Use of the McGill PainQuestionnaire in the assessment of cancer pain: replicability and consistency. Pain 1980; 8 (3): 377-87 (Pubitemid 10071340)
20. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994; 23 (2): 129-38
21. Ashburn MA, Lipman AG. Management of pain in the cancer patient. Anesth Analg 1993; 76 (2): 402-16 (Pubitemid 23085754)
22. Weiner D, Peterson B, Ladd K, et al. Pain in nursing home residents: an exploration of prevalence, staff perspectives, and practical aspects of measurement. Clin J of Pain 1999; 15 (2): 92-101 (Pubitemid 29265941)
23. Ezenwa MO, Ameringer S, Ward SE, et al. Racial and ethnic disparities in pain management in the United States. J Nurs Scholarsh 2006; 38 (3): 225-33 (Pubitemid 44252876)
24. Gatchel RJ, Peng YB, Peters ML, et al. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull 2007; 133 (4): 581-624
25. Cutler RB, Fishbain DA, Lu Y, et al. Prediction of pain center treatment outcome for geriatric chronic pain patients. Clin J of Pain 1994; 10 (1): 10-7 (Pubitemid 24079527)
26. Glock M, Friedman R, Myers P. Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia: January 1985 through July 1995: 1147 citations. 2nd ed. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section, 1995
27. Mystakidou K, Tsilika E, Parpa E, et al. Exploring the relationships between depression, hopelessness, cognitive status, pain, and spirituality in patients with advanced cancer. Arch Psychiatr Nurs 2007; 21 (3): 150-61
28. Mercadante S. Predictive factors and opioid responsiveness in cancer pain. Eur J Cancer 1998; 34 (5): 627-31 (Pubitemid 28218935)
29. Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003; 97 (S3): 866-73 (Pubitemid 36125825)
30. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002 Dec; 100 (3): 213-7 (Pubitemid 35449233)
31. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep 2006; 10 (1): 67-70
32. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 2000; 4 (1): 5-15 (Pubitemid 30230790)
33. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 2: basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage 2001; 21 (3): 255-64 (Pubitemid 32192946)
34. Mercadante S, Arcuri E, Ferrera P, et al. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 2005; 30 (5): 485-91 (Pubitemid 41718968)
35. World Health Organization (WHO). Cancer pain relief. 2nd ed. Geneva: WHO, 1996
36. Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22 (1): 185-92 (Pubitemid 41095131)
37. Bellville JW, Forrest WH, Miller E, et al. Influence of age on pain relief from analgesics. JAMA 1971; 217 (13): 1835-41
38. Gloth III FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc 2001; 49 (2): 188-99
39. Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol 1992; 32 (1): 271-302
40. Ward SE, Goldberg N, Miller-McCauley V, et al. Patientrelated barriers to management of cancer pain. Pain 1993; 52 (3): 319-24 (Pubitemid 23080550)
41. Herr KA, Garand L. Assessment and measurement of pain in older adults. Clin Geriatr Med 2001; 17 (3): 457-vi
42. Lansbury G. Chronic pain management: a qualitative study of elderly people's preferred coping strategies and barriers to management. Disabil Rehabil 2000; 22 (1-2): 2-14 (Pubitemid 30037784)
43. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. JAMA 1995; 274 (23): 1870-3
44. Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician 2009; 12 (1): 269-80
45. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42 (6): 1364-72 (Pubitemid 43260039)
46. Mercadante S, Casuccio A, Agnello A, et al. Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. J Pain Symptom Manage 1999; 17 (5): 351-6 (Pubitemid 29239526)
47. Miranda HF, Silva E, Pinardi G. Synergy between the antinociceptive effects of morphine and NSAIDs. Can J Physiol Pharmacol 2004; 82 (5): 331-8 (Pubitemid 39093699)
48. Joishy SK, Walsh D. The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. J Pain Symptom Manage 1998; 16 (5): 334-9 (Pubitemid 28545915)
49. Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer 2002; 38 (10): 1358-63 (Pubitemid 34686847)
50. Israel FJ, Parker G, Charles M, et al. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, doubleblind, placebo-controlled, crossover trial. J Pain Symptom Manage 2010; 39 (3): 548-54
51. Prommer E. Hydrocodone: does it have a role in palliative care? J Opioid Manag 2010; 6 (4): 295-9
52. Leppert W, uczak J. The role of tramadol in cancer pain treatment: a review. Support Care Cancer 2005; 13 (1): 5-17 (Pubitemid 40193060)
53. Prommer EE. Tramadol: does it have a role in cancer pain management? J Opioid Manag 2005; 1 (3): 131-8
54. Pedersen RS, Damkier P, Brøsen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006; 62 (7): 513-21
55. Cossmann M, Kohnen C, Langford R, et al. Tolerance and safety of tramadol use: results of international studies and data from drug surveillance [in French]. Drugs 1997; 53 Suppl. 2: 50-62 (Pubitemid 27176579)
56. Gourlay GK. Advances in opioid pharmacology. Support Care Cancer 2005; 13 (3): 153-9 (Pubitemid 40468961)
57. Rodriguez RF, Castillo JM, Castillo MP, et al. Hydrocodone/ acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clin J of Pain 2008; 24 (1): 1-4
58. Kalso E. Oxycodone. J Pain Symptom Manage 2005; 29 (5): 47-56
59. Rodriguez RF, Castillo JM, del Pilar Castillo M, et al. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study. Clin Ther 2007; 29 (4): 581-7 (Pubitemid 47018268)
60. Grond S, Radbruch L, Meuser T, et al. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999; 18 (3): 174-9 (Pubitemid 29459122)
61. Omar Tawfik M, Elborolossy K, Nasr F. Tramadol hydrochloride in the relief of cancer pain: a double blind comparison against sustained release morphine. Pain 1990; 41 Suppl. 5: S377
62. Bono AV, Cuffari S. Effectiveness and tolerance of tramadol in cancer pain: a comparative study with respect to buprenorphine. Drugs 1997; 53 Suppl. 2: 40-9 (Pubitemid 27174067)
63. Dhaliwal HS, Sloan P, Arkinstall WW, et al. Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. J Pain Symptom Manage 1995; 10 (8): 612-23
64. Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician 2008; 11 (2 Suppl.): S133-53 (Pubitemid 351682083)
65. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81 (3): 429-44 (Pubitemid 46364493)
66. Lötsch J. Opioid metabolites. J Pain Symptom Manage 2005; 29 (5): 10-24
67. Radbruch L, Trottenberg P, Elsner F, et al. Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project. PalliatMed 2011; 25 (5): 578-96
68. Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61 (15): 2289-307 (Pubitemid 34074808)
69. Vasisht N, Gever LN, Tagarro I, et al. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig 2009; 29 (10): 647-54
70. Collins SL, Faura CC, Moore RA, et al. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998; 16 (6): 388-402 (Pubitemid 29006202)
71. Stuart-Harris R, Joel SP, McDonald P, et al. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol 2000; 49 (3): 207-14 (Pubitemid 30150981)
72. Klepstad P, Kaasa S, Skauge M, et al. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand 2000; 44 (6): 656-64 (Pubitemid 30413411)
73. De Conno F, Ripamonti C, Fagnoni E, et al. The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain. Palliat Med 2008; 22 (3): 214-21 (Pubitemid 351795925)
74. Gatti A, Reale C, Occhioni R, et al. Standard therapy with opioids in chronic pain management: ORTIBER study. Clin Drug Investig 2009; 29 Suppl. 1: 17-23
75. National Comprehensive Cancer Network guidelines: adult cancer pain. Version 2.2011. Fort Washington (PA): National Comprehensive Cancer Network, 2011
76. Radbruch L, Loick G, Schulzeck S, et al. Intravenous titration with morphine for severe cancer pain: report of 28 cases. Clin J of Pain 1999; 15 (3): 173-8 (Pubitemid 29467547)
77. Mercadante S, Ferrera P, Villari P, et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009; 37 (4): 632-41
78. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 2001; 22 (2): 67-70 (Pubitemid 32149274)
79. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidencebased report. J Clin Oncol 2001; 19 (9): 2542-54 (Pubitemid 32391226)
80. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358 (22): 2332-43 (Pubitemid 351749157)
81. Peuckmann-Post V, Elsner F, Krumm N, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2010 Nov 10; (11): CD006788
82. Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid induced sedation. Pain Med 2003; 4 (2): 135-40
83. Prommer EE. Methadone for cancer pain. Palliative Care: Research and Treatment 2010; 4: 1-10
84. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005; 19 (4): 13-24
85. Prommer E. Opioid rotation: logical choices for pain that is poorly responsive to morphine. Prog Palliat Care 2009; 17 (3): 111-6
86. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996; 64 (2): 293-302 (Pubitemid 26130869)
87. Ehrnrooth E, Grau C, Zachariae R, et al. Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer. Acta Oncol 2001; 40 (6): 745-50 (Pubitemid 33081984)
88. Mercadante S, Arcuri E, Tirelli W, et al. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori 2002; 88 (3): 239-42 (Pubitemid 34875452)
89. Kautio AL, Haanpaa M, Saarto T, et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008; 35 (1): 31-9 (Pubitemid 350299098)
90. Preskorn SH, Irwin HA. Toxicity of tricyclic antidepressants - kinetics, mechanism, intervention: a review. J Clin Psychiatry 1982; 43 (4): 151-6 (Pubitemid 12156642)
91. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42 (2): 135-44 (Pubitemid 20258898)
92. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52 (5): 547-52
93. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy. Neurology 2003; 60 (8): 1284-9
94. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002; 6 (1): 17-24
95. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001; 57 (9): 1583-8 (Pubitemid 33055474)
96. Prommer EE. Tapentadol: an initial analysis. J Opioid Manag 2010; 6 (3): 223-6
97. Heimdal K, Hirschberg H, Slettebø H, et al. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol 1992; 12 (2): 141-4
98. Sorensen PS, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30 (1): 22-7 (Pubitemid 24058082)
99. Loblaw DA, Wu JSY, Kirkbride P, et al. Pain flare in patients with bone metastases after palliative radiotherapy - nested randomized control trial. Support Care Cancer 2007; 15 (4): 451-5 (Pubitemid 46697018)
100. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002; 6: 61-8
101. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004; 22 (14): 2909-17 (Pubitemid 41079911)
102. Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000; 60 (1): 23-33 (Pubitemid 30598818)
103. Yajnik S, Singh GP, Singh G, et al. Phenytoin as a coanalgesic in cancer pain. J Pain Symptom Manage 1992; 7 (4): 209-13
104. Dunteman ED. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies. J Pain Palliat Care Pharmacother 2005; 19 (1): 35-43 (Pubitemid 40594048)
105. Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo- controlled trial, N01C3. Cancer 2008; 112 (12): 2802-8 (Pubitemid 351969227)
106. Guay DRP. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001; 21 (9): 1070-81 (Pubitemid 32807868)
107. Bruera E, Ripamonti C, Brenneis C, et al. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage 1992; 7 (3): 138-40
108. Sharma S, Rajagopal MR, Palat G, et al. A phase II pilot study to evaluate use of intravenous lidocaine for opioidrefractory pain in cancer patients. J Pain Symptom Manage 2009; 37 (1): 85-93
109. Sloan P, Basta M, Storey P, et al. Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain. Anesth Analg 1999; 89 (3): 760-1 (Pubitemid 29409837)
110. Ripamonti C, Bruera E. Pain and symptom management in palliative care. Cancer Control 1996; 3 (3): 204-13 (Pubitemid 26233999)
111. Wallace MS, Magnuson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: a doubleblind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000; 25 (5): 459-67
112. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999; 80 (3): 533-8 (Pubitemid 29182702)
113. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002; 36 (2): 236-40 (Pubitemid 34126813)
114. Portenoy RK, McCaffery M. Adjuvant analgesics. In: Doyle D, Hanks G, Cherny N, et al., editors. Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1993: 187-203
115. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001; 429 (1-3): 71-8 (Pubitemid 33043983)
116. Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000; 20 (4): 246-52
117. Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol 2008; (182): 313-33
118. Sikora K, Advani S, Koroltchouk V, et al. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol 1999; 10 (4): 385-90 (Pubitemid 29236414)
119. Schmid RL, Sandler AN, Katz J. Use and efficacy of lowdose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999; 82 (2): 111-25 (Pubitemid 29317524)
120. Okon T. Ketamine: an introduction for a pain and palliative medicine physician. Pain Physician 2007; 10 (3): 493-500 (Pubitemid 46971302)
121. Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. Edinburgh: British Pain Society, 2005: 8-11
122. Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel- group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with in-tractable cancer-related pain. J Pain Symptom Manage 2010; 39 (2): 167-79
123. Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today 2006; 42 (8): 495-503 (Pubitemid 44508066)
124. Schreiber S, Getslev V, Backer MM, et al. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav 1999; 64 (1): 75-80 (Pubitemid 29415798)
125. Khojainova N, Santiago-Palma J, Kornick C, et al. Olanzapine in the management of cancer pain. J Pain Symptom Manage 2002; 23 (4): 346-50 (Pubitemid 34462947)
126. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60 (11): 1524-34 (Pubitemid 37443116)
127. Prommer EE. Toxicity of bisphosphonates. J Palliat Med 2009; 12 (11): 1061-5
128. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7 (5): 377-87 (Pubitemid 33759002)
129. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94 (19): 1458-68
130. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334 (8): 488-93 (Pubitemid 26067736)
131. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21 (16): 3150-7 (Pubitemid 46606297)
132. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer Clin Oncol 1991; 27 (8): 954-8
133. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium- 153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16 (4): 1574-81 (Pubitemid 28175783)
134. Prommer EE. Established and potential therapeutic applications of octreotide in palliative care. Support Care Cancer 2008; 16 (10): 1117-23
135. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000; 18 (8): 1780-99 (Pubitemid 30220558)
136. Miguel R. Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control 2000; 7 (2): 149-56 (Pubitemid 30196852)
137. Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004; 291 (9): 1092-9 (Pubitemid 38541686)
138. Bruera E, Brenneis C, Michaud M, et al. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 1988; 62 (2): 407-11
139. Ripamonti C, Zecca E, Brunelli C, et al. Rectal methadone in cancer patients with pain. Ann Oncol 1995; 6 (8): 841-3
140. Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 1995; 80 (2): 296-302
141. De Conno F, Ripamonti C, Saita L, et al. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 1995; 13 (4): 1004-8
142. Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 44 (3): 335-42
143. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scandinavica 2002; 46 (7): 759-70 (Pubitemid 34803193)
144. Shelley K, Paech MJ. The clinical applications of intranasal opioids. Curr Drug Deliv 2008; 5 (1): 55-8 (Pubitemid 351225634)
145. Reisfield GM, Wilson GR. Rational use of sublingual opioids in palliative medicine. J Palliat Med 2007; 10 (2): 465-75 (Pubitemid 46740220)
146. Krajnik M, Zylicz Z, Finlay I, et al. Potential uses of topical opioids in palliative care-report of 6 cases. Pain 1999; 80 (1-2): 121-5 (Pubitemid 29151696)